Breast Cancer Clinical Trial
— MuLi_RTOfficial title:
Music Listening to Reduce Anxiety and Stress in Patients Undergoing Radiotherapy
| Verified date | January 2022 |
| Source | Istituti Clinici Scientifici Maugeri SpA |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Music and music therapy are now widely used as non-pharmacological intervention techniques in different clinical and therapeutic settings. The present study includes the use of musical listening related to the concept of "Music Medicine", a possibility of modifying the psycho-physiological state of the patient through the targeted use of musical pieces respondent to specific parameters and musical structures able to interact in particular conditions with the psycho-somatic imbalances to which the person is subjected. In particular, in this study, in addition to proposing a traditional listening method, the music used in one of the research arms will be composed of an artificial intelligence called "Melomics-Health". The objective of the study is to verify whether the perception of anxiety and stress in cancer patients undergoing Radiotherapy is influenced by music listening ("Melomics-Health" music vs listening to favorite music). Sixty breast cancer surgical patients, candidates for post-operative radiotherapy with a healing purpose. Patients who will undergo Radiation therapy for the first time in their lives will be included. Patients will be recruited in this randomized controlled study with a sequential enrollment and, in the case of inclusion, will be assigned to one of the following 3 groups: a) "Melomics-Health" music listening group (n = 20); b) favorite music listening group (n = 20); c) no-music control group (n = 20). Music groups will undergo 15 minutes music listening immediately before the simulation and the first 5 sessions of radiotherapy. Patients will be subjected to a psychological assessment focused on anxiety (State-Trait Anxiety Inventory) and distress (Psychological Distress Inventory) dimensions at the baseline (T0), at the end of the treatments (T1) and at the Follow-up (T2, 2 weeks after the fifth session of Radiotherapy). A specific questionnaire will also be submitted to the patients included in music groups. This questionnaire will allow the music therapist to acquire specific qualitative information regarding the different types of music listening and the responses of the subjects to them. Descriptive statistics will be produced for all the variables detected.The effectiveness of musical listening in relation to the psychological aspects considered will be evaluated by applying analysis of variance models.
| Status | Completed |
| Enrollment | 60 |
| Est. completion date | September 30, 2020 |
| Est. primary completion date | June 30, 2020 |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | N/A and older |
| Eligibility | Inclusion Criteria: - patients who will undergo Radiation therapy for the first time in their lives - patients who are candidates for hypofractionated partial breast irradiation with a duration of at least 10 sessions - patients who signed the informed consent Exclusion Criteria: - patients with associated diseases that preclude the understanding of the study contents (eg patients with established psychiatric disorders and / or with significant cognitive deficits) - patients with significant hearing loss - patients already previously subjected to music therapy or therapy based on music listening - patients with musical skills (musical training or musical practice> 3 years). - patients who are candidates for hypofractionated partial breast irradiation with a duration equal to or less than 10 sessions |
| Country | Name | City | State |
|---|---|---|---|
| Italy | Istituti Clinici Scientifici Maugeri SpA | Pavia | Lombardy |
| Lead Sponsor | Collaborator |
|---|---|
| Istituti Clinici Scientifici Maugeri SpA | University of Pavia |
Italy,
Bradt J, Dileo C, Magill L, Teague A. Music interventions for improving psychological and physical outcomes in cancer patients. Cochrane Database Syst Rev. 2016 Aug 15;(8):CD006911. doi: 10.1002/14651858.CD006911.pub3. Review. Update in: Cochrane Database Syst Rev. 2021 Oct 12;10:CD006911. — View Citation
Bradt J, Dileo C, Shim M. Music interventions for preoperative anxiety. Cochrane Database Syst Rev. 2013 Jun 6;(6):CD006908. doi: 10.1002/14651858.CD006908.pub2. Review. — View Citation
Chen LC, Wang TF, Shih YN, Wu LJ. Fifteen-minute music intervention reduces pre-radiotherapy anxiety in oncology patients. Eur J Oncol Nurs. 2013 Aug;17(4):436-41. doi: 10.1016/j.ejon.2012.11.002. Epub 2012 Dec 4. — View Citation
Clark M, Isaacks-Downton G, Wells N, Redlin-Frazier S, Eck C, Hepworth JT, Chakravarthy B. Use of preferred music to reduce emotional distress and symptom activity during radiation therapy. J Music Ther. 2006 Fall;43(3):247-65. — View Citation
Morasso G, Costantini M, Baracco G, Borreani C, Capelli M. Assessing psychological distress in cancer patients: validation of a self-administered questionnaire. Oncology. 1996 Jul-Aug;53(4):295-302. — View Citation
O'Callaghan C, Sproston M, Wilkinson K, Willis D, Milner A, Grocke D, Wheeler G. Effect of self-selected music on adults' anxiety and subjective experiences during initial radiotherapy treatment: a randomised controlled trial and qualitative research. J Med Imaging Radiat Oncol. 2012 Aug;56(4):473-7. doi: 10.1111/j.1754-9485.2012.02395.x. Epub 2012 May 28. — View Citation
Raglio A, Oddone E, Meaglia I, Monti MC, Gnesi M, Gontero G, Imbriani C, Ivaldi GB. Conventional and Algorithmic Music Listening before Radiotherapy Treatment: A Randomized Controlled Pilot Study. Brain Sci. 2021 Dec 8;11(12). pii: 1618. doi: 10.3390/brai — View Citation
Raglio A, Vico F. Music and Technology: The Curative Algorithm. Front Psychol. 2017 Nov 24;8:2055. doi: 10.3389/fpsyg.2017.02055. eCollection 2017. — View Citation
Rossetti A, Chadha M, Torres BN, Lee JK, Hylton D, Loewy JV, Harrison LB. The Impact of Music Therapy on Anxiety in Cancer Patients Undergoing Simulation for Radiation Therapy. Int J Radiat Oncol Biol Phys. 2017 Sep 1;99(1):103-110. doi: 10.1016/j.ijrobp.2017.05.003. Epub 2017 May 8. — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Anxiety reduction | Difference in State-Trait Anxiety Inventory (STAI) score. There are 2 subscales within this measure: 1) the State Anxiety Scale (S-Anxiety) evaluating the current state of anxiety; 2) the Trait Anxiety Scale (T-Anxiety) evaluating relatively stable aspects of "anxiety proneness". Range of scores for each subtest is 20-80, the higher score indicating greater anxiety. | Baseline (T0) vs 2 weeks (T1, i.e. end of radiotherapy treatment) | |
| Secondary | Anxiety reduction | Difference in State-Trait Anxiety Inventory (STAI) score. There are 2 subscales within this measure: 1) the State Anxiety Scale (S-Anxiety) evaluating the current state of anxiety; 2) the Trait Anxiety Scale (T-Anxiety) evaluating relatively stable aspects of "anxiety proneness". Range of scores for each subtest is 20-80, the higher score indicating greater anxiety. | Baseline (T0) vs 4 weeks (T2, two weeks after the end of radiotherapy treatment) | |
| Secondary | Stress reduction | Difference in Psychological Distress Inventory (PDI) score. Score range is from 13 (low distress level) to 65 (high distress level). | Baseline (T0) vs 2 weeks (T1, i.e. end of radiotherapy treatment) | |
| Secondary | Stress reduction | Difference in Psychological Distress Inventory (PDI) score. Score range is from 13 (low distress level) to 65 (high distress level). | Baseline (T0) vs 4 weeks (T2, two weeks after the end of radiotherapy treatment) |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |